Recall: Atovaquone

Apr. 2023Pharmacy Updates
Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension, USP 750 mg/5 mL, lot #E220182 with an expiration date of 12/2023, due to possible bacterial contamination in the product. This drug is used for the prevention and treatment of a lung infection called Pneumocystis jiroveci pneumonia (PCP) in adults and children 13 years old and older who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole. Read the full text of the Atovaquone recall.

Recent Announcements

UPMC Dental Advantage celebrates 15-years of growth

From pilot program to now serving all product lines
Jan. 2026What's New

ACA Risk Adjustment Claims Submission Announcement

Notice: Submit your claims for ACA members
Jan. 2026Important Notices

Register for the Oral Health in Your Pediatric Office CME - accredited webinar

Please join us for a live, CME-accredited webinar on Wednesday, March 11 from noon to 1 p.m. that will provide an overview of oral health in your pediatric office. Providers with a(n) MD/DO, PA, CRNP, RN, or LPN may also apply for topical fluoride certification after completion of this course.
Jan. 2026Education/Webinars